Table 1 Delphi panel characteristics (n = 300)

From: Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response

Characteristic

Number of panellists (%)

Age

30 to <40 years

40 to <50 years

50 to <60 years

>60 years

101 (33.7)

91 (30.3)

67 (22.3)

41 (13.7)

Gender

Women

Men

Non-binary or gender diverse

Prefer not to say

143 (47.7)

154 (51.3)

3 (1.0)

0

Country of origin, by income level

Low or middle

High

Prefer not to say

92 (30.7)

194 (64.7)

14 (4.6)

Global region of origin

East Asia and Pacific

Europe and Central Asia

Latin America and Caribbean

Middle East and North Africa

North America

South Asia

Sub-Saharan Africa

Prefer not to say

47 (15.7)

140 (46.7)

27 (9.0)

13 (4.3)

54 (18.0)

16 (5.3)

3 (1.0)

0

Country of work, by income level

Low or middle

High

Prefer not to say

83 (27.7)

201 (67.0)

16 (5.3)

Global region of work

East Asia and Pacific

Europe and Central Asia

Latin America and Caribbean

Middle East and North Africa

North America

South Asia

Sub-Saharan Africa

Prefer not to say

45 (15.0)

141 (47.0)

28 (9.3)

8 (2.7)

67 (22.3)

7 (2.3)

2 (0.7)

2 (0.7)

Primary sector of employment

Academic

Public

Private

Civil society

Prefer not to say

Other

102 (34.0)

105 (35.0)

73 (24.3)

6 (2.0)

2 (0.7)

12 (4.0)

Field(s) of employment

Clinical research

Non-clinical research

Health-care provider

Patient or policy advocacy

Education

Prefer not to say

Other

74 (24.7)

11 (3.7)

164 (54.7)

15 (5.0)

13 (4.3)

3 (1.0)

20 (6.6)

Years working in the IBD field

1–11

12–22

23–33

34–44

45–55

Prefer not to say

133 (44.3)

83 (27.7)

51 (17.0)

22 (7.3)

1 (0.3)

10 (3.3)

Area of national professional association/society membership(s) in the country of work

Gastroenterology

227 (75.7)

Immune-mediated inflammatory disorders (e.g. rheumatology, dermatology, ophthalmology dealing with patients with IBD)

10 (3.3)

Epidemiology

5 (1.7)

Primary care

4 (1.3)

Patient advocacy and/or policy advocacy

23 (7.7)

Prefer not to say

4 (1.3)

Other

27 (9.0)

  1. IBD, inflammatory bowel disease.